189 related articles for article (PubMed ID: 16722631)
1. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Becker OM; Dhanoa DS; Marantz Y; Chen D; Shacham S; Cheruku S; Heifetz A; Mohanty P; Fichman M; Sharadendu A; Nudelman R; Kauffman M; Noiman S
J Med Chem; 2006 Jun; 49(11):3116-35. PubMed ID: 16722631
[TBL] [Abstract][Full Text] [Related]
2. Optimization of (arylpiperazinylbutyl)oxindoles exhibiting selective 5-HT₇ receptor antagonist activity.
Volk B; Gacsályi I; Pallagi K; Poszávácz L; Gyönös I; Szabó E; Bakó T; Spedding M; Simig G; Szénási G
J Med Chem; 2011 Oct; 54(19):6657-69. PubMed ID: 21859099
[TBL] [Abstract][Full Text] [Related]
3. Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.
de Paulis T
Curr Opin Investig Drugs; 2007 Jan; 8(1):78-86. PubMed ID: 17263189
[TBL] [Abstract][Full Text] [Related]
4. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Vicente B; Sanz AM; Hernández M; Orensanz L
J Med Chem; 1999 Jan; 42(1):36-49. PubMed ID: 9888831
[TBL] [Abstract][Full Text] [Related]
6. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
[TBL] [Abstract][Full Text] [Related]
7. Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects.
Iyer GR; Reinhard JF; Oshana S; Kauffman M; Donahue S
J Clin Pharmacol; 2007 Jul; 47(7):817-24. PubMed ID: 17495280
[TBL] [Abstract][Full Text] [Related]
8. Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety.
Russell MG; Carling RW; Street LJ; Hallett DJ; Goodacre S; Mezzogori E; Reader M; Cook SM; Bromidge FA; Newman R; Smith AJ; Wafford KA; Marshall GR; Reynolds DS; Dias R; Ferris P; Stanley J; Lincoln R; Tye SJ; Sheppard WF; Sohal B; Pike A; Dominguez M; Atack JR; Castro JL
J Med Chem; 2006 Feb; 49(4):1235-8. PubMed ID: 16480260
[TBL] [Abstract][Full Text] [Related]
9. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
Jurczyk S; Kołaczkowski M; Maryniak E; Zajdel P; Pawłowski M; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E; Bojarski AJ; Charakchieva-Minol S; Duszyńska B; Nowak G; Maciag D
J Med Chem; 2004 May; 47(10):2659-66. PubMed ID: 15115407
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Bang-Andersen B; Ruhland T; Jørgensen M; Smith G; Frederiksen K; Jensen KG; Zhong H; Nielsen SM; Hogg S; Mørk A; Stensbøl TB
J Med Chem; 2011 May; 54(9):3206-21. PubMed ID: 21486038
[TBL] [Abstract][Full Text] [Related]
11. 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1.
Carling RW; Moore KW; Street LJ; Wild D; Isted C; Leeson PD; Thomas S; O'Connor D; McKernan RM; Quirk K; Cook SM; Atack JR; Wafford KA; Thompson SA; Dawson GR; Ferris P; Castro JL
J Med Chem; 2004 Mar; 47(7):1807-22. PubMed ID: 15027873
[TBL] [Abstract][Full Text] [Related]
12. Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
Zajdel P; Subra G; Bojarski AJ; Duszyńska B; Tatarczyńska E; Nikiforuk A; Chojnacka-Wójcik E; Pawłowski M; Martinez J
Bioorg Med Chem; 2007 Apr; 15(8):2907-19. PubMed ID: 17321139
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents.
Abou-Gharbia MA; Childers WE; Fletcher H; McGaughey G; Patel U; Webb MB; Yardley J; Andree T; Boast C; Kucharik RJ; Marquis K; Morris H; Scerni R; Moyer JA
J Med Chem; 1999 Dec; 42(25):5077-94. PubMed ID: 10602693
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C
J Med Chem; 1998 Dec; 41(25):5070-83. PubMed ID: 9836623
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
Czopek A; Byrtus H; Kołaczkowski M; Pawłowski M; Dybała M; Nowak G; Tatarczyńska E; Wesołowska A; Chojnacka-Wójcik E
Eur J Med Chem; 2010 Apr; 45(4):1295-303. PubMed ID: 20060623
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.
Zagórska A; Kołaczkowski M; Bucki A; Siwek A; Kazek G; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pawłowski M
Eur J Med Chem; 2015 Jun; 97():142-54. PubMed ID: 25965777
[TBL] [Abstract][Full Text] [Related]
17. High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity.
Maurel JL; Autin JM; Funes P; Newman-Tancredi A; Colpaert F; Vacher B
J Med Chem; 2007 Oct; 50(20):5024-33. PubMed ID: 17803293
[TBL] [Abstract][Full Text] [Related]
18. Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality.
Jacobsen EJ; Stelzer LS; TenBrink RE; Belonga KL; Carter DB; Im HK; Im WB; Sethy VH; Tang AH; VonVoigtlander PF; Petke JD; Zhong WZ; Mickelson JW
J Med Chem; 1999 Apr; 42(7):1123-44. PubMed ID: 10197957
[TBL] [Abstract][Full Text] [Related]
19. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 2-fluoro and 3-trifluoromethyl-phenyl-piperazinylalkyl derivatives of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione as potential antidepressant agents.
Zagórska A; Bucki A; Kołaczkowski M; Siwek A; Głuch-Lutwin M; Starowicz G; Kazek G; Partyka A; Wesołowska A; Słoczyńska K; Pękala E; Pawłowski M
J Enzyme Inhib Med Chem; 2016; 31(sup3):10-24. PubMed ID: 27353547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
